Collider Bias Undermines Our Understanding of COVID-19 Disease Risk and Severity

Concerns about dermarolling potentially causing collagen breakdown and cancer, with skepticism about the claims due to lack of scientific evidence. Users express doubts and discuss the validity of the article's claims.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

RU58841 is absorbed systemically in humans, contradicting claims it stays local, but no harm is proven. Alternatives like CB-03-01 or KX-826, especially with finasteride, are suggested for safety.

RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.